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Szeged, Hungary
Accepted for publication 7 April 1998
Summary A 7-year-old girl with generalized erythematous, scaling plaques and vesiculobullous lesions on the
extremities was diagnosed as having pemphigus foliaceus. Lesional direct immunofluorescence
revealed intercellular IgG, IgA and C3 deposition. The patient’s serum gave positive reactions against
one epitope of desmoglein 3 and the epitope of desmoglein 1 in enzyme-linked immunosorbent
assays, but the blood sample for indirect immunofluorescence did not display any circulating
antibodies. The patient was successfully treated systemically with prednisolone and dapsone.
Currently, she is taking dapsone, 12·5 mg daily. She has been free of lesions for the last 3 years.
Pemphigus, a life-threatening autoimmune blistering
disorder that involves the skin and mucous membranes,
can be divided into two major subgroups: pemphigus
vulgaris (PV) and pemphigus foliaceus (PF).1,2 PF, a
superficial variant of pemphigus, is extremely rare in
children and mostly occurs in the middle-aged and
elderly.3,4 The clinical findings in childhood PF involve
gradually spreading eczematized scaly plaques starting
on the face and upper extremities, with the possible
development of bullae and superficial crusts.5 Early
diagnosis and prompt treatment are based on the
clinical, histological and immunopathological changes.
Case report
A 7-year-old girl presented with a 3-month history of
generalized, painful, small blisters and superinfected
erosions covered with thick, yellowish crusts. For
months, there had been a history of red, squamous
plaques on the scalp, which were treated as psoriasis
with local corticosteroids; the lesions healed slowly. The
patient was weak and in a poor condition. Physical
examination revealed extensive, generalized erythema,
with superficial erosions covered with thick yellow
crusts, mainly on the face (Fig. 1a), trunk (Fig. 2) and
extremities. Scattered intact superficial blisters were
present on the extremities, with a positive Nikolsky’s
sign. The oral mucosa was spared. Bilateral cervical and
axillary lymphadenopathy was also noted.
Laboratory investigations revealed the following
abnormalities: leucocytosis with a white blood cell
count of 20·7 (109/L (normal 4·6–10·2), an aspartate
aminotransferase level of 74 U/L (normal <40 U/L) and
an alanine aminotransferase level of 83 U/L (normal
<40 U/L). Skin and pharyngeal swabs for bacterial
cultures were positive for Staphylococcus aureus and
Streptococcus pyogenes.
A perilesional biopsy for histology demonstrated a
subcorneal blister with acantholytic cells without any
inflammatory cells in the cleft (Fig. 3). Direct immuno-
fluorescence studies of frozen skin tissue showed posi-
tive intercellular staining for IgG, IgA and C3 within the
epidermis. The circulating antidesmoglein 1 (anti-Dsg1)
and anti-Dsg3 antibodies were examined by means of
enzyme-linked immunosorbent assays (ELISAs), using
synthetic, antigenic peptides. Antigenic epitopes for
desmogleins 1 and 3 were chosen using PeptideStructure
software. The antigenic epitope for desmoglein 1 con-
sists of 14 amino acids. It is part of the extracellular (EII)
domain located between two Ca2þ binding sequences.
The antigenic epitope for Dsg3 consists of 13 amino
acids. It is located in the extracellular (EI) domain and is
part of the Bos1 sequence.6
Antigenic peptides were dissolved in phosphate-buf-
fered saline (PBS), pH 7·4, in 0·1 mg/100 mL concentra-
tion. Microplate wells were filled with 100 mL and
allowed to coat overnight at 4 8C. Plates were washed
twice with distilled water, and the remaining binding
sites were blocked with 1% bovine serum albumin (BSA)
in PBS for 1·5 h at 37 8C. Plates were washed again
three times with PBS–Tween (PBS containing 0·5%
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Tween-20), and 100 mL of the 200 times diluted serum
samples was added per well, incubated for 1 h at 37 8C
and washed extensively with PBS–Tween. Aliquots of
100 mL of peroxidase-conjugated antihuman IgG, diluted
1 : 5000 in PBS–Tween, were then added to each well
and incubated for 1 h at 37 8C. Subsequently, the plates
were washed again with PBS–Tween and then 100 mL of
substrate solution [17 mg of ortho-phenylene diamine
(OPD) dissolved in 50 mL of phosphate–citric acid
buffer, pH 5, and 20 mL of H2O2] was added to each
well and the colour allowed to develop for 10 min at
room temperature in the dark. The reaction was stopped
by adding 50 mL of 4 N H2SO4 to each well. Plates were
read on an ELISA reader at 492 nm.
In ELISA investigations, serum samples were tested in
triplicate, and the mean results were taken. Ten healthy
control sera were used in each microplate. Autoanti-
body positivity was accepted when special ELISA optical
density was higher than the mean value of controls
increased by two standard deviations. The patient’s
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Figure 1. (a) Seborrhoeic-like, erythematous, scaling lesions are seen
on the face. (b) Complete recovery with mild hyperpigmentation on
the cheek.
Figure 2. Diffuse, exfoliative, crusted, eroded plaques are evident on
the trunk.
serum gave positive reactions against one epitope of
Dsg3 and the epitope of Dsg1. Blood samples for indirect
immunofluorescence studies demonstrated no circulat-
ing antibodies. The patient’s circulating anti-epidermal
antibodies were also examined by the Western blot
technique to detect Dsg1 or Dsg3, but there was no
positive reaction.
A diagnosis of PF was made and treatment was
commenced with 50 mg/day prednisolone. This treat-
ment resulted in only a slow remission, and we therefore
combined the corticosteroid with 12·5 mg of dapsone
twice a day. In a few days, there was a satisfactory fast
resolution of the blistering and a rapid improvement in
the condition occurred. The dose of prednisolone was
subsequently tapered slowly to half the initial dose. One
month was sufficient for almost complete recovery (Fig.
1b), and blood investigations returned to normal. The
patient was discharged while receiving 25 mg of pred-
nisolone every second day, and 12·5 mg of dapsone
twice daily. This treatment has been tapered so that
she is now receiving 12·5 mg of dapsone a day. She has
had no further lesions over the last 3 years.
Discussion
PF, a less severe variant of pemphigus, is a rare disease,
especially in the first 14 years; it affects both sexes
equally5,7–10 Despite its rarity, however, it is more fre-
quent in Brazil11 and India.12 Adult PF has been
reported to be associated with other autoimmune dis-
orders13,14 and drugs,15 but Graves’ disease is the only
condition reported to coexist with childhood PF.9
The clinical manifestations of adult and juvenile PF
are similar. The onset is often slow, with crusting,
yellowish, scaling lesions starting on the face and
scalp, as in our case,8 which can mimic impetigo and
seborrhoeic dermatitis; unlike PV, the oral mucosa is
rarely involved.5,7 Histologically, PF is characterized by
acantholysis high in the epidermis, either subcorneally
or in the stratum granulosum.16 These superficial
changes are similar in PF and pemphigus erythe-
matosus (PE) but, clinically, PE may simulate lupus
erythematosus.17,18 Our case demonstrated the typical
histology of PF, with acantholysis in the upper epider-
mis. PF in general gives identical immunofluorescence
(IF) changes to PV. Staining of the PF lesions for direct IF
shows the intercellular deposition of IgG, C3 and, rarely,
IgA,19 as detected in our case. Serum from PF patients
for indirect IF studies shows IgG staining of the kera-
tinocyte cell surface in the upper epidermis.2
The pathogenesis of blister formation in pemphigus is
related to the detection of autoantibody formation
against PF antigen Dsg1 (160 kDa) and the PV antigen
Dsg3 (130 kDa).20 Immunoblot analysis in PF patients
revealed circulating autoantibodies against Dsg1 anti-
gen; despite its potential positivity, the reaction was
negative in two-thirds of the patients.21 These antigenic
determinations including Dsg1 and Dsg3 are important
in differentiation from other autoimmune blistering
diseases such as PV2 or PE, which are not usually
determined in PE.18 Therefore, detection of the charac-
teristical anti-epidermal and anti-Dsg antibodies can
support the diagnosis. In our case, investigation of the
serum circulating antibodies using the Western blot
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Figure 3. Acantholysis is present in the granular
layer, with basophilic acantholytic cells inside
the cleft (haematoxylin and eosin, original
magnification, × 100).
technique did not detect any positive reaction but,
based on more recent studies with ELISA,22,23 we also
routinely examined the circulating anti-Dsg1 and anti-
Dsg3 antibodies by means of ELISA using synthetic,
antigenic peptides.24 The patient’s serum gave positive
reactions against one epitope of Dsg3 and the epitope of
Dsg1. We used these antigenic epitopes in more than
30 cases, and 68% of the sera from patients with
pemphigus gave a specific reaction with these epitopes
using the ELISA technique.
PF, the less severe form of pemphigus, may be treated
simply with topical steroids or low-dose corticosteroids;7
the more generalized form of PF has been treated with
high-dose corticosteroids.9,25 However, Basset et al.26
reported satisfactory results with dapsone as initial
therapy. We also achieved fast remission when we
added dapsone to low-dose corticosteroids. We believe
that PF is rare in childhood and has a good prognosis.
As Basset et al.26 reported, we also achieved a good
result with dapsone therapy. In our case, the lesions
disappeared in response to a combination of dapsone
and low-dose corticosteroids.
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